Annual Shareholders’ Meeting - Bio-Techne · Annual Shareholders’ Meeting October 29, ... share...
Transcript of Annual Shareholders’ Meeting - Bio-Techne · Annual Shareholders’ Meeting October 29, ... share...
Disclaimer Cautionary Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made herein relate to, among other things, future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions, benefits of investments and partnerships, business strategies and other matters. Such statements can be identified by words such as: “expected,” “expects,” “expect,” “forecast,” “would,” “estimate,” “will,” or similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results could differ materially from those stated or implied in the forward-looking statements. For a list of factors, risks and uncertainties which could make our actual results differ from expected results, please see our latest Annual Report on Form 10-K. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, as a result of new information, future developments or otherwise. This presentation also contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For definitions of applicable non-GAAP financial measures and reconciliations of non-GAAP financial information to GAAP financial information, see the Reconciliations of GAAP to Non-GAAP Financial Measures included in the Company’s financial reports on Forms 10-Q and 10-K and related press releases.
2
Introductions
Business Meeting
Business Overview
Financial Report
Questions and Answers
Recognition of Howard O’Connell
Agenda
3
4
Corporate Leadership Team
Dr. Fernando Bazan Chief Technology
Officer
Gerry Andros Vice President
Sales
Peter Breloer Vice President
Asia Pacific
Ruth Bright Managing Director
R&D Systems Europe
5
Corporate Leadership Team
Brenda Furlow Senior Vice President and General Counsel
Dave Eansor Sr. Vice President Biotech Division
Bob Gavin Senior Vice President
Protein Platforms
Kevin Gould Vice President
Cliniqa
Dr. Frank Mortari Vice President
Corporate Development
6
Corporate Leadership Team
Jim Hippel Chief Financial
Officer
Dr. Ruyi Hao Vice President and Corporate Scientist
Dave LePage Chief Information
Officer
7
Corporate Leadership Team
Dr. Dave Peters Managing Director
Tocris
Dr. Kevin Reagan Vice President
Operations and Product Development
Struan Robertson Vice President
Human Resources
Karen Padgett Vice President
Marketing
8
Corporate Leadership Team
Marcel Veronneau Senior Vice President
Clinical Controls
Dr. Wendy Shao Managing Director
R&D Systems China
Dr. Diane Wotta Senior Director
Quality and Regulatory Affairs
9
Bio-Techne Board Members
Robert Baumgartner, Chairman Dr. Roger Lucas, Vice Chair Dr. Charles Dinarello John Higgins Dr. Karen Holbrook Dr. Roeland Nusse Howard O’Connell Dr. Randolph Steer Harold Wiens
Global footprint • Minneapolis, MN, based • 1400+ employees worldwide • Offices in North America, Europe and China
Leadership position in cytokine/growth factors, immunoassays and small molecules
Deep product portfolio and applications expertise
Provider of biological reagents and instruments for a variety of life science applications
One of three manufacturers of clinical blood controls
Key recent acquisitions and investments: ProteinSimple, Novus, PrimeGene, Bionostics, Cyvek and Cliniqa
Fiscal Year Ends: June 30
FY 2015 Revenues: $452M
FY 2015 Gross Margin: 71.4%
FY 2015 Adj. Earnings: $127M
FY 2015 Adjusted EPS: $3.40
Current Market Cap: $3.6B
12
Current Business Overview
13
Bio-Techne Mission
To provide the Life Sciences community with innovative, high-quality, scientific tools to better
understand biological processes and drive discovery
Building on the Techne Legacy • Targeted acquisitions to build on the legacy
brands and expand our product portfolio in specified markets
• Build on our leadership position in Proteins and Assays to a recognized leader in Antibodies and Multiplex solutions
• Recognized leader in quality and delivery of biological content to both industrial and academic customers globally
• Expansion of our Clinical Controls capabilities and products
Attractive Financial Returns • Revenues $1B
• Organic revenue CAGR 10%
• Including Acquisitions: EBITDA 40%
• Re-investment in R&D = 9-10% of Revenues
• 28% of sales in Asia-Pacific vs. 14%
• Margin decrease acceptable in exchange for accelerated revenue growth
Goal To be recognized globally for providing quality biological content and leverage this strength to enter diagnostic and adjacent markets
Strategy Leverage our deep product development and manufacturing capabilities to deliver innovative, disruptive and more complete solutions for the markets we serve utilizing our industry-leading channels and gap-filling acquisitions to address customers’ life science research and diagnostic needs
Achievement of annual revenues in excess of $1B within five years and demonstrate improvement in the vitality index (NPVI of >10% of sales from products introduced in last three years)
Success
14
Strategic Plan Summary (2014 – 2019)
Core Products and Innovation
Geographic Expansion
Commercial Execution
Operational Excellence
Talent Recruitment
and Retention
• First to market quality products at the leading edge of researchers’ needs
• Continued investment of 9-10% of revenues into research activities
• Leverage strong balance sheet - gain access to new technologies to deploy our content
• Drive collaborations through Key Opinion Leaders (KOLs)
• Continued expansion of sales force in China
• Opening of sales office in Beijing
• Low-cost China manufacturing capabilities
• Expansion in Latin America
• Expand new Protein Platforms division in Europe and China
• Local sales staff in key US regional hubs
• SEA distribution managed locally
• Investment in key tools and instruments that drive additional consumables revenue
• Expand distribution channels through Fisher and VWR agreements
• Leverage large ProteinSimple sales force
• Creating a manufacturing organization to extract efficiencies in production
• Realignment of reporting groups within Bio-Techne to create more efficient operations
• Introduce new Business and ERP systems to company
• Key management hiring (Divisions SVP, CTO, VP Sales, VP Marketing, VP HR, VP Asia Pacific, Finance Directors, etc.)
• Implement compensation structures to attract and retain top talent
• Expansion and retention in Asia
• Staffing of legal office
• Addition of new talent through acquisitions
Strategy Summary
16
17
Core Reagents Clinical Controls and IVD
Cell-Based Controls Proteins Antibodies Assays Small Molecules
Protein Platforms
Low-cost protein manufacturing in
China
~250,000 additional Abs and digital
platform
Immunoassay automation and
multiplexing
Blood chemistry, blood and IVD
controls
SIMPLE PLEX
Products and Technology Expansion
Targets with ROIC > WACC
Targets that fill perceived gaps
Sound prioritization strategy
Healthy hopper of targets
M&A Strategy
18
Closed PrimeGene – April 2014 Closed Novus and ProteinSimple – July 2014
Closed CyVek – November 2014 Closed Cliniqa – July 2015
Number of Bio-Techne Sites: 21 Integration of Novus into Bio-Techne Operations
Integration of CyVek into ProteinSimple
Significant Achievements in Last Two Years
19
Allen Pierce – Vice President Operations, ProteinSimple Dave Eansor – Sr. Vice President, Biotech
Ellen Scipta – Sr. Director of Finance Gerry Andros – America and Europe Commercial
Karen Padgett – Vice President, Marketing Kason Klumpyan – Corporate Controller
Kevin Gould – Vice President, Cliniqa Peter Breloer – Vice President, Asia Pacific
Struan Robertson – Vice President, Human Resources
Significant Achievements in Last Two Years
20
Tocris New Building New Website and Chat Line
New ERP and Hyperian Systems Financial Consolidation Processes
Employee Count 1400+ First Leadership Development Training
Replacing All Computers – 54% Complete United Way Donation $50K+
Operations Efficiencies $2MM
Significant Achievements in Last Two Years
21
1684 New Products in 2015 = $5.8MM FY15 Revenue Growth 3.6%
FY15 Adjusted EBITDA growth 9.0% China achieves >$25MM sales
Fisher sales exceed $35MM NA Academic sales get back to positive territory
Patent Committee meetings resulting in patent filings Solid Investor Relations program with >100 meetings
Significant Achievements in Last Two Years
22
Community Affairs
23
Financial Trends
Organic Sales Growth1 2% 6% 2% 0% 3% 4%
1Organic sales exclude the impact of acquisitions and foreign currency exchange rates
25
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
$0
$50
$100
$150
$200
$250
$300
$350
$400
$450
$500
FY10 FY11 FY12 FY13 FY14 FY15
Revenue ($Mil)
EBITDA ($Mil)
EBITDA Margin (%)
TECH vs. S&P 500
Share Performance vs. Market
Overall, historical stock price performance has out-performed S&P500 26
~ 72% of Sales High 70s Gross Margin%
Low 50s Op. Margin%
~ 15% of Sales High 60s Gross Margin%
High single-digit Op. Margin%
~ 13% of Sales Mid 40s Gross Margin% Low 30s Op. Margin%
• R&D Systems • Tocris • Boston Biochem • BiosPacific • PrimeGene • Novus
Clinical Controls
Biotechnology
FY 2015 Reportable Segments
Protein Platforms • ProteinSimple • CyVek
27
CCD Minneapolis CCD Devens Cliniqa (beg. FY16)
USA Europe China Pacific Rim ROW
53%
24%
10% 6% 7%
FY 2015 Biotech Segment Sales by Geography
+3% growth
flat growth
+24% growth
(2%) growth
28
Solid organic growth in core businesses: Margins impacted by acquisitions, EPS impacted by FX headwinds
29
Fiscal Year 2015 Financial Highlights
($MM)
Organic growth impacted by OEM shipment timing; Margins and EPS impacted by acquisitions
30
Q1 FY16 Financial Highlights
($MM)
The brands under the Bio-Techne name have a strong, global
recognition built on the reputation of being long term quality reagents
suppliers. As we have acquired additional strong brands and
technologies they have allowed us to re-defined ourselves for our
customers and offer them an extended product portfolio that
accommodated more of their needs. As a more complete solution
solutions provider to our loyal customers we believe we can derive
greater economic and see our products transition from the research
bench to the clinical lab. These are some of the changes we are
implementing at Bio-Techne to drive long term growth. 31
Conclusion
31
Howard O’Connell
In Appreciation of 35 years of
Distinguished Service
33 33
Bio-Techne Board Retirement